Goldsmith D J, Sandooran D, Short C D, Mallick N P, Johnson R W
Renal Unit, Manchester Royal Infirmary, United Kingdom.
Am J Kidney Dis. 1996 Aug;28(2):278-82. doi: 10.1016/s0272-6386(96)90314-5.
AL-amyloidosis has a poor prognosis, typically with cardiac or renal failure ensuing some months after diagnosis. However, sporadically there have been reports of long-term survivors, either with unusual manifestations of amyloidosis, or after concerted chemotherapy to suppress the overt or occult pathological monoclonal plasma cell population responsible for the elaboration of immunoglobulin light chains. We report the case of a 46-year-old man who has survived 21 years after the histological diagnosis of renal amyloidosis was made, after he had presented with severe nephrotic syndrome. This patient was given intensive chemotherapy but came to end-stage renal failure some 10 years later, was dialysed for 1 year, and then was the successful recipient of a cadaveric renal transplant, which is working excellently some 10 years later, with little evidence of recurrent renal or systemic amyloidosis. There is renewed interest in therapy for systemic amyloidosis, and this case demonstrates that with this approach the prognosis can be more favorable than is commonly assumed.
AL型淀粉样变性预后较差,通常在诊断后数月内会出现心力衰竭或肾衰竭。然而,偶尔也有长期存活者的报道,这些患者要么有淀粉样变性的不寻常表现,要么是在进行联合化疗以抑制产生免疫球蛋白轻链的明显或隐匿的病理性单克隆浆细胞群体之后。我们报告一例46岁男性患者,在出现严重肾病综合征后,经组织学诊断为肾淀粉样变性,已存活21年。该患者接受了强化化疗,但约10年后发展为终末期肾衰竭,接受了1年透析,随后成功接受了尸体肾移植,10年后移植肾功能良好,几乎没有肾或系统性淀粉样变性复发的迹象。目前对系统性淀粉样变性的治疗重新产生了兴趣,该病例表明,采用这种方法,预后可能比通常认为的更有利。